Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.55 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.53 |
| ▸ | DPP4 | P27487 | 4/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.51 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684179 | 0.97 | NOD1 (0.52) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29382397 | 0.96 | NOD1 (0.54) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29843198 | 0.94 | NOD1 (0.56) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29371375 | 0.94 | NOD1 (0.56) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31674332 | 0.93 | NOD1 (0.52) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29376967 | 0.91 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL2850058 | 0.90 | DPP7 (0.58) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29376792 | 0.90 | DPP7 (0.58) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31256792 | 0.89 | FOLH1 (0.60) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL30101988 | 0.89 | FOLH1 (0.60) | NOD1DPP8DPP9DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | claimed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | claimed |
| EP-3581583-B1 | PHARMACEUTICAL COMPOUND | VALLAURIX PTE LTD (SG) | 2022-02-23 | — | — | EP | claimed |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-07-31 | — | — | US | disclosed |
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20240382614-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240269269-A1 | Self-Assembling Nanoparticles | VACCITECH NORTH AMERICA, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4355367-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES FOR DRUG DELIVERY APPLICATIONS | Barinthus Biotherapeutics North America, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-116171282-A | Soluble NPY2 receptor agonists | 勃林格殷格翰国际有限公司 | 2023-05-26 | — | — | CN | disclosed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022266340-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES FOR DRUG DELIVERY APPLICATIONS | VACCITECH NORTH AMERICA, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220162259-A1 | PEPTIDE COMPLEX AND PRODUCTION METHOD THEREFOR, AND USE OF SAID PEPTIDE COMPLEX | KANEKA CORPORATION (JP) | 2022-05-26 | — | — | US | disclosed |
| US-11286288-B2 | Pharmaceutical compound | VALLAURIX PTE. LTD. (SG) | 2022-03-29 | — | — | US | disclosed |
| EP-3581583-B1 | PHARMACEUTICAL COMPOUND | VALLAURIX PTE LTD (SG) | 2022-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127887-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides | IAPP, BRCA1, ANXA11 | NOD1 112/4885DPP8 1837/4885DPP9 1790/4885 |
| US-20240269269-A1 | Self-Assembling Nanoparticles | UBE2B, CD4, UBE2G2 | NOD1 114/4885DPP8 2826/4885DPP9 3673/4885 |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | NOD1 1790/4885DPP8 3462/4885DPP9 3415/4885 |
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | NOD1 643/4885DPP8 1159/4885DPP9 1180/4885 |
| US-20240382614-A1 | Self-Assembling Nanoparticles Based On Amphiphilic Peptides for Drug Delivery Applications | ANXA11, ANXA1, IAPP | NOD1 329/4885DPP8 2985/4885DPP9 2922/4885 |
| US-20220162259-A1 | PEPTIDE COMPLEX AND PRODUCTION METHOD THEREFOR, AND USE OF SAID PEPTIDE COMPLEX | VIP, FURIN, IAPP | NOD1 602/4885DPP8 126/4885DPP9 416/4885 |
| US-20250242015-A1 | SELF-ASSEMBLING NANOPARTICLES | UBE2B, CD4, HRH1 | NOD1 112/4885DPP8 2853/4885DPP9 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.